Discovery could lead to more treatments to prevent cancer and infectious diseases
Posted: 18 July 2023 Researchers have cracked how a particular type of immune cell develops in the body and protects against infection and disease. And the discovery could help in the development of more preventive treatments, according to…
From science fiction to reality: new bionic limb research redefines possibilities for people with amputations
Posted: 14 July 2023 In a world-first, a patient with an amputation above the elbow has been able to control a bionic hand as if it was his own thanks to new surgical and engineering advancements merging humans…
IDT’s strong quarter delivers growth
Posted: 13 July 2023 Pharmaceutical manufacturer IDT Australia is seeing a surge in sales as demand for medical cannabis products rises and companies seek out more capable contract development and manufacturing organisations (CDMO). The Melbourne company told investors…
Monash-Alfred-Baker join forces to improve heart health
Posted: 13 July 2023 A new cardiovascular research centre is bringing together Monash University, the Baker Heart and Diabetes Institute and Alfred Health to boost opportunities for academic-clinician partnered research and offer new pathways for emerging research talent in the Alfred Research Alliance Precinct.…
Monash University buys CSIRO’s Parkville property; Australia’s biomedical research sector set to expand
Posted: 13 July 2023 Monash University has acquired a prime Parkville property that will become a key addition to its Parkville campus – home to Monash’s world-leading Faculty of Pharmacy and Pharmaceutical Sciences – and significantly advance Australia’s…
Professor Mark Dawson receives prestigious grant
Posted: 13 July 2023 Professor Mark Dawson, Head of Cancer Epigenetics Laboratory at Peter Mac has been awarded a Translational Research Program (TRP) grant worth USD $750,000 to further his research to help overcome acquired resistance to anti-cancer…
Published trial results find Atmo Gas Capsule can detect changes in regional colonic fermentation in IBS patients
Posted: 11 July 2023 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced results from a clinical study have found that its gas-sensing capsule can…
Dimerix Receives Approval for Paediatric Investigation Plan from the EMA
Posted: 10 July 2023 Dimerix Limited (ASX: DXB), a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases, today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) accepted its Paediatric Investigation Plan (PIP)…
New AD-214 Data Links Phase I Results with Efficacy, De-risks Clinical Dosing Schedule
Posted: 7 July 2023 ASX Announcement Key points: New data favourably links AD-214 preclinical animal studies and Phase I human clinical trial results to provide important dose frequency insights AD-214 is designed to treat fibrotic diseases such as…
“Jumar Bioincubator” calls for next-gen biotechs, appoints new GM
Posted: 4 July 2023 Australia’s newest biotech incubator is calling for innovative early-stage Australian biotechs to take up residency in its much-awaited Melbourne-based facility. The “Jumar Bioincubator” will be supported by cash and in-kind contributions of approximately $45 million over…
Dimerix Confirms Phase 3 FSGS Kidney Disease Stud Design Appropriate For China
Posted: 4 July 2023 Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical study in inflammatory disease, today confirmed that the Chinese regulatory agency, National Medical Products Administration (NMPA) has provided a written response on…
Neuren completes enrolment in Phelan-McDermid syndrome Phase 2 trial
Posted: 4 July 2023 Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome has now been completed. Topline results from the trial are expected to be…
